Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
The latest projects newly into human trials include BNT3212.
But results come from a curated dataset, with no in-trial comparator.
A common mutation comes into play for PRMT5 inhibition.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Tolerability could decide first-line therapy in EGFRm disease.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
